Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma
Clinical trial NCT07763171 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07763171
- Sponsor
- Gruppo Oncologico del Nord-Ovest
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-01
- Primary completion
- 2029-09-01
- Enrollment
- 244
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.